1. A patient with long-standing type 2 diabetes mellitus has marked beta-cell failure (very low C-peptide) and inadequate control despite a maximally dosed sulfonylurea. The team is deciding whether adding an SGLT-2 inhibitor will help or whether the failing beta cells make further oral therapy futile. Which reasoning correctly predicts the outcome?
A) An SGLT-2 inhibitor will be ineffective for the same reason the sulfonylurea is failing, because both classes ultimately depend on adequate endogenous insulin secretion to lower glucose
B) An SGLT-2 inhibitor will work only if the sulfonylurea is first replaced by exogenous insulin, because SGLT-2 inhibitors require a circulating insulin floor to produce glycosuria
C) An SGLT-2 inhibitor retains glucose-lowering efficacy here because its glycosuric mechanism is insulin-independent, whereas the sulfonylurea is failing precisely because it relies on residual beta-cell insulin secretion that is now exhausted
D) Neither agent can help, because all oral antidiabetic drugs act exclusively by augmenting insulin secretion
E) An SGLT-2 inhibitor will lower glucose only by stimulating the failing beta cells more strongly than the sulfonylurea does, overcoming the secretory deficit
ANSWER: C
Rationale:
The key integration is that the two classes depend on different mechanisms. A sulfonylurea lowers glucose by closing beta-cell ATP-sensitive potassium channels to drive insulin secretion, so it fails as beta-cell function is exhausted. An SGLT-2 inhibitor lowers glucose by blocking renal proximal-tubule glucose reabsorption and forcing glycosuria, a mechanism that does not depend on insulin secretion or action; it therefore retains efficacy even with profound beta-cell failure.
Option A: Option A is incorrect because it wrongly assigns an insulin-secretion dependence to SGLT-2 inhibitors; their glycosuric mechanism is insulin-independent.
Option B: Option B is incorrect because SGLT-2 inhibitors do not require a circulating insulin floor to produce glycosuria; glucose excretion proceeds based on filtered glucose load and transporter blockade.
Option D: Option D is incorrect because not all oral agents act by augmenting insulin secretion; SGLT-2 inhibitors and metformin, for example, do not.
Option E: Option E is incorrect because SGLT-2 inhibitors do not act by stimulating beta cells at all; they do not augment insulin secretion.
2. Two weeks after starting an SGLT-2 inhibitor for diabetic kidney disease, a patient's estimated glomerular filtration rate (eGFR) has dropped modestly from 52 to 46 mL/min/1.73 m2. The patient is asymptomatic and volume-replete. How should this finding be interpreted, integrating the drug's renal mechanism?
A) This is an expected, largely reversible hemodynamic dip caused by tubuloglomerular feedback: increased distal sodium delivery constricts the afferent arteriole and lowers intraglomerular pressure, the same mechanism that produces long-term renoprotection, so therapy should generally be continued
B) This indicates acute tubular necrosis from direct nephrotoxicity and the drug must be permanently discontinued and never re-trialed
C) This reflects efferent arteriolar constriction raising intraglomerular pressure, an early warning of accelerated nephron loss requiring urgent intervention
D) This is an unexpected finding with no mechanistic explanation and most likely represents laboratory error that can be ignored without further thought
E) This means the drug has caused volume overload and the eGFR decline reflects dilutional change that will worsen with continued therapy
ANSWER: A
Rationale:
This requires integrating the tubuloglomerular feedback mechanism with the clinical monitoring picture. SGLT-2 inhibition reduces proximal sodium reabsorption, increasing sodium delivery to the macula densa and activating tubuloglomerular feedback, which constricts the afferent arteriole and lowers intraglomerular pressure. The result is a modest, largely reversible early dip in eGFR that reflects the very hemodynamic effect responsible for long-term renoprotection; in an asymptomatic, volume-replete patient, therapy is generally continued.
Option B: Option B is incorrect because the dip is a predictable hemodynamic effect, not acute tubular necrosis or direct nephrotoxicity mandating permanent discontinuation.
Option C: Option C is incorrect because it inverts the mechanism: SGLT-2 inhibition constricts the afferent arteriole and lowers (not raises) intraglomerular pressure.
Option D: Option D is incorrect because the finding has a clear mechanistic explanation and should not be dismissed as error.
Option E: Option E is incorrect because SGLT-2 inhibitors produce natriuresis and volume reduction, not volume overload, so a dilutional explanation is wrong.
3. A patient with diabetic kidney disease and albuminuria is already on a maximally tolerated angiotensin receptor blocker. The nephrologist adds an SGLT-2 inhibitor. What is the best integrated rationale for combining these two agents for renal protection?
A) The two agents are redundant because both act on the efferent arteriole, so the combination adds no protection beyond the angiotensin receptor blocker alone
B) The two agents reduce intraglomerular pressure at different nodes of the glomerular circuit: the angiotensin receptor blocker dilates the efferent arteriole while the SGLT-2 inhibitor constricts the afferent arteriole, so the combination lowers intraglomerular hypertension through complementary, non-redundant mechanisms
C) The combination should be avoided because constricting the afferent arteriole and dilating the efferent arteriole act in opposition and cancel each other's renal benefit
D) The SGLT-2 inhibitor protects the kidney only by improving glycemic control, so its renal benefit is fully captured by the patient's existing diabetes therapy and the angiotensin receptor blocker
E) The angiotensin receptor blocker constricts the afferent arteriole and the SGLT-2 inhibitor dilates the efferent arteriole, so the two together raise filtration fraction and improve clearance
ANSWER: B
Rationale:
The integration is the two-node model of intraglomerular pressure control. An angiotensin receptor blocker (a renin-angiotensin-aldosterone system blocker) reduces intraglomerular pressure chiefly by dilating the efferent arteriole, whereas an SGLT-2 inhibitor reduces it by constricting the afferent arteriole through tubuloglomerular feedback. Because they act on different arterioles, their effects are complementary and additive rather than redundant, which is the basis for combining them in diabetic kidney disease.
Option A: Option A is incorrect because the agents do not both act on the efferent arteriole; they act on different nodes and are not redundant.
Option C: Option C is incorrect because acting on different arterioles does not cancel benefit; both maneuvers lower intraglomerular pressure and the effects are complementary.
Option D: Option D is incorrect because SGLT-2 inhibitor renoprotection is substantially hemodynamic and independent of glycemic improvement, so it is not captured by glucose control alone.
Option E: Option E is incorrect because it inverts both mechanisms and wrongly claims a rise in filtration fraction; the combination lowers intraglomerular pressure rather than raising filtration fraction.
4. A 70-year-old with heart failure with reduced ejection fraction and chronic kidney disease (eGFR 32 mL/min/1.73 m2, albuminuria) has no diabetes and a normal HbA1c. A colleague says no SGLT-2 inhibitor can be used because the eGFR is below the glycemic threshold of about 45 and the patient is not diabetic. Integrating the indication-specific eGFR floors and the diabetes requirement, what is the correct conclusion?
A) The colleague is correct: with eGFR 32 and no diabetes, every SGLT-2 inhibitor is contraindicated and the patient should receive none
B) The patient must first be made "eligible" by initiating metformin to create a glycemic indication before any SGLT-2 inhibitor can be considered
C) Only canagliflozin may be used, because it is the agent approved for heart failure and chronic kidney disease in patients without diabetes
D) Dapagliflozin or empagliflozin can be started for the heart failure and chronic kidney disease indications: those indications do not require diabetes, and their cardiorenal eGFR floors (roughly 20 to 25 mL/min/1.73 m2) are below this patient's eGFR, so the ~45 glycemic threshold does not govern this decision
E) The patient is eligible only if the eGFR can first be raised above 45 mL/min/1.73 m2, since that threshold applies to all indications regardless of agent
ANSWER: D
Rationale:
This integrates two separate rules. First, dapagliflozin and empagliflozin are approved for heart failure and chronic kidney disease (CKD) regardless of diabetes status, so the absence of diabetes does not preclude use. Second, the eGFR floor is indication-specific: the roughly 45 mL/min/1.73 m2 figure is the glycemic threshold, whereas the cardiorenal indications for these two agents extend down to about 20 to 25 mL/min/1.73 m2. With an eGFR of 32, the patient is above the cardiorenal floor, so dapagliflozin or empagliflozin can be started for outcome benefit.
Option A: Option A is incorrect because the glycemic threshold and diabetes requirement do not apply to the cardiorenal indications, which permit use here.
Option B: Option B is incorrect because no glycemic indication or metformin prerequisite is needed for the cardiorenal indications.
Option C: Option C is incorrect because canagliflozin's non-glycemic approval is for diabetic kidney disease and requires diabetes; dapagliflozin and empagliflozin are the diabetes-independent cardiorenal agents.
Option E: Option E is incorrect because the ~45 threshold is glycemic-specific, not a universal floor across all indications, so it does not govern this cardiorenal decision.
5. A patient with type 2 diabetes mellitus has both established atherosclerotic cardiovascular disease (prior stroke) and heart failure. Integrating the distinct cardiovascular mechanisms of the two major outcome-proven drug classes, which regimen and rationale is most appropriate?
A) An SGLT-2 inhibitor alone is sufficient, because its benefit pattern covers atherosclerotic stroke as effectively as it covers heart failure
B) A glucagon-like peptide-1 receptor agonist alone is sufficient, because it reduces heart failure hospitalization as its dominant benefit
C) Neither class should be used because their cardiovascular mechanisms are antagonistic and would offset each other in a patient with both conditions
D) Two SGLT-2 inhibitors should be combined to cover both the atherosclerotic and heart failure components of the patient's risk
E) Combine an SGLT-2 inhibitor (whose cardiovascular benefit is predominantly hemodynamic and heart-failure-oriented) with a glucagon-like peptide-1 receptor agonist (whose benefit is predominantly anti-atherosclerotic, notably reducing stroke and major adverse cardiovascular events); the two classes are complementary
ANSWER: E
Rationale:
This integrates the contrasting cardiovascular outcome trial signals. SGLT-2 inhibitors reduce cardiovascular risk predominantly through a hemodynamic, heart-failure-oriented mechanism (reduced heart failure hospitalization and cardiovascular death), whereas glucagon-like peptide-1 receptor agonists reduce risk predominantly through an anti-atherosclerotic mechanism, notably reducing stroke and major adverse cardiovascular events. In a patient with both atherosclerotic disease and heart failure, combining the two classes addresses both risk pathways, and they are complementary.
Option A: Option A is incorrect because the SGLT-2 inhibitor benefit is heart-failure-oriented and does not robustly cover atherosclerotic stroke.
Option B: Option B is incorrect because reducing heart failure hospitalization is the SGLT-2 inhibitor signal, not the dominant glucagon-like peptide-1 receptor agonist benefit.
Option C: Option C is incorrect because the two classes are complementary, not antagonistic, and are appropriately combined.
Option D: Option D is incorrect because two SGLT-2 inhibitors should never be combined, and doing so would not address the atherosclerotic component.
6. In the landmark empagliflozin cardiovascular outcome trial, the reduction in cardiovascular death emerged within weeks of starting the drug. What does this rapid time course allow you to infer about the underlying mechanism?
A) The rapid benefit confirms an anti-atherosclerotic mechanism, because plaque regression and stabilization occur within days of initiating effective therapy
B) The rapid benefit is inconsistent with an atherosclerosis-slowing mechanism (which would take months to years) and instead points to a hemodynamic mechanism such as volume unloading and reduced cardiac filling pressures
C) The rapid benefit indicates the effect was due to improved glycemic control, since HbA1c falls within the first week and directly prevents cardiovascular death
D) The rapid benefit proves the drug works mainly by lowering low-density lipoprotein cholesterol, an effect that reduces events within days
E) The rapid benefit shows the mechanism is reversal of established myocardial fibrosis, which resolves within the first weeks of therapy
ANSWER: B
Rationale:
This is a mechanistic inference from timing. Atherosclerosis-modifying effects (plaque regression or stabilization) act over months to years, so a cardiovascular death benefit appearing within weeks cannot plausibly be explained by slowing atherosclerosis. The rapid onset instead points to a hemodynamic mechanism such as volume unloading, natriuresis, and reduced cardiac filling pressures, consistent with the heart-failure-oriented benefit of the class.
Option A: Option A is incorrect because plaque regression and stabilization do not occur within days; an anti-atherosclerotic mechanism would not produce a benefit on this time scale.
Option C: Option C is incorrect because the mortality benefit is too rapid and too large to be explained by modest glycemic improvement, and glucose lowering does not directly prevent cardiovascular death on this time course.
Option D: Option D is incorrect because SGLT-2 inhibitors are not low-density lipoprotein-lowering agents and do not act through lipid reduction.
Option E: Option E is incorrect because reversal of established myocardial fibrosis does not occur within weeks and is not the explanation for the rapid benefit.
7. A large SGLT-2 inhibitor trial enrolls a population that is predominantly at risk-factor level, with only a minority having established atherosclerotic disease. Based on the consistent pattern seen across the SGLT-2 inhibitor cardiovascular outcome program, which result is most likely?
A) The atherosclerotic major adverse cardiovascular event composite is likely to be neutral (non-significant), while the benefit is most likely to appear in the heart failure hospitalization component, including the composite of cardiovascular death or heart failure hospitalization
B) A large, highly significant reduction in non-fatal stroke is the most likely dominant finding, mirroring the benefit pattern of incretin-based therapies
C) The drug is most likely to significantly increase major adverse cardiovascular events in a lower-risk population, failing the cardiovascular safety criterion
D) The most likely finding is a large reduction in non-fatal myocardial infarction driven by rapid plaque stabilization
E) No endpoint, including heart failure hospitalization, is likely to show any benefit in a population without established atherosclerotic disease
ANSWER: A
Rationale:
This applies the generalizable pattern of the SGLT-2 inhibitor program: the benefit is consistently driven by reductions in heart failure hospitalization (and the composite of cardiovascular death or heart failure hospitalization), whereas the atherosclerotic major adverse cardiovascular event (MACE) composite is often neutral, particularly in populations with a low proportion of established atherosclerotic disease. The predicted result is therefore a neutral MACE composite with benefit appearing in the heart failure component.
Option B: Option B is incorrect because a dominant stroke reduction is the incretin (glucagon-like peptide-1 receptor agonist) pattern, not the SGLT-2 inhibitor pattern.
Option C: Option C is incorrect because SGLT-2 inhibitors have consistently met cardiovascular safety criteria rather than increasing MACE.
Option D: Option D is incorrect because the class does not act through rapid plaque stabilization and myocardial infarction reduction is not its characteristic benefit.
Option E: Option E is incorrect because heart failure hospitalization benefit is observed even in lower-atherosclerotic-risk populations, so a complete absence of benefit is not the expected result.
8. A patient with type 2 diabetes mellitus on an SGLT-2 inhibitor starts a strict ketogenic (very-low-carbohydrate) diet and, three days later, develops nausea and fatigue with a plasma glucose of 168 mg/dL. Integrating the mechanism of euglycemic diabetic ketoacidosis with this precipitant, what is the correct understanding and action?
A) The near-normal glucose rules out ketoacidosis, so the symptoms can be attributed to the diet and no ketone testing is needed
B) The ketogenic diet is protective against euglycemic ketoacidosis in this setting, so the SGLT-2 inhibitor can be safely continued without monitoring
C) A carbohydrate-restricted state plus relative insulin deficiency can precipitate euglycemic diabetic ketoacidosis on an SGLT-2 inhibitor (glucagon-driven ketogenesis with glycosuria preventing hyperglycemia); ketones should be measured despite the near-normal glucose, and the drug held if ketoacidosis is confirmed
D) The symptoms indicate simple hypoglycemia and should be treated with additional carbohydrate while continuing the drug at a higher dose
E) The presentation reflects expected osmotic diuresis only and requires nothing more than increased oral fluids
ANSWER: C
Rationale:
This integrates the pathophysiology of euglycemic diabetic ketoacidosis (DKA) with a classic precipitant. Carbohydrate restriction and relative insulin deficiency promote glucagon-driven hepatic ketogenesis, while the glycosuric effect of the SGLT-2 inhibitor prevents glucose accumulation, so ketoacidosis can develop with only modestly elevated or near-normal glucose. The correct action is to measure ketones despite the near-normal glucose and hold the drug if ketoacidosis is confirmed.
Option A: Option A is incorrect because a near-normal glucose does not exclude euglycemic DKA; that is the central diagnostic pitfall.
Option B: Option B is incorrect because a ketogenic diet is a precipitant of, not protection against, euglycemic DKA in this setting.
Option D: Option D is incorrect because the picture is not simple hypoglycemia, and increasing the SGLT-2 inhibitor dose would worsen ketoacidosis risk.
Option E: Option E is incorrect because these symptoms warrant ketone measurement rather than reassurance as benign osmotic diuresis.
9. An 80-year-old with baseline low-normal blood pressure is taking a loop diuretic and an angiotensin-converting enzyme inhibitor. An SGLT-2 inhibitor is being added. Integrating the volume effects of these agents, what is the most appropriate initiation strategy?
A) Start the SGLT-2 inhibitor at the maximum dose and add a second antihypertensive simultaneously, since the combination poses no volume-related risk in the elderly
B) Withhold the SGLT-2 inhibitor permanently, because it can never be used in any patient taking a loop diuretic or a renin-angiotensin system blocker
C) Increase the loop diuretic dose at the same time the SGLT-2 inhibitor is started, to pre-empt the fluid retention that SGLT-2 inhibitors characteristically cause
D) Anticipate additive volume depletion: initiate at a lower dose with blood pressure monitoring and consider reducing the concurrent loop diuretic, because the osmotic diuresis and natriuresis of the SGLT-2 inhibitor compound the volume loss from the diuretic and the vasodilatory effect of the renin-angiotensin blocker, especially in an elderly patient with low baseline blood pressure
E) No precautions are needed because SGLT-2 inhibitors raise blood pressure and will offset the hypotensive effects of the other two agents
ANSWER: D
Rationale:
This integrates the volume effects of three agents. SGLT-2 inhibitors cause osmotic diuresis and natriuresis, which compound the volume loss from a loop diuretic and the blood-pressure-lowering effect of a renin-angiotensin system blocker; volume depletion is most clinically significant in elderly patients, those on loop diuretics or renin-angiotensin-aldosterone system blockers, and those with low baseline blood pressure. The appropriate strategy is to initiate at a lower dose with blood pressure monitoring and to consider reducing the concurrent diuretic.
Option A: Option A is incorrect because starting at maximum dose and adding another antihypertensive ignores the additive volume-depletion risk.
Option B: Option B is incorrect because SGLT-2 inhibitors can be used with loop diuretics and renin-angiotensin blockers with appropriate precautions; permanent avoidance is unwarranted.
Option C: Option C is incorrect because SGLT-2 inhibitors cause volume loss, not fluid retention, so increasing the loop diuretic would worsen depletion.
Option E: Option E is incorrect because SGLT-2 inhibitors modestly lower, not raise, blood pressure, so they add to rather than offset the hypotensive risk.
10. A patient on an SGLT-2 inhibitor arrives for urgent surgery; the team notes a normal preoperative plasma glucose and considers this reassuring against perioperative ketoacidosis. Integrating the mechanism of euglycemic ketoacidosis with perioperative care, which reasoning is correct?
A) A normal preoperative glucose reliably excludes perioperative ketoacidosis, so the SGLT-2 inhibitor poses no metabolic risk and no further testing is required
B) A normal preoperative glucose is falsely reassuring, because euglycemic diabetic ketoacidosis can occur with near-normal glucose; ketones should be checked in any patient on an SGLT-2 inhibitor before urgent surgery, and for elective surgery the drug should have been held 3 to 4 days in advance rather than relying on the glucose value
C) The glucose value is irrelevant because SGLT-2 inhibitors cannot cause any perioperative metabolic complication
D) The drug should be continued and the dose increased perioperatively to maintain tight glucose control during fasting, which prevents ketoacidosis
E) Perioperative ketoacidosis on this class is always accompanied by markedly elevated glucose, so a normal glucose definitively excludes it
ANSWER: B
Rationale:
This integrates the euglycemic mechanism with perioperative management. Because SGLT-2 inhibitor-associated ketoacidosis can develop with only near-normal glucose, a normal preoperative glucose is falsely reassuring; ketones should be measured in any patient on the drug presenting for urgent surgery, and for elective surgery the protocol is to hold the agent 3 to 4 days beforehand rather than relying on the glucose value.
Option A: Option A is incorrect because a normal glucose does not exclude euglycemic ketoacidosis, which is the central pitfall.
Option C: Option C is incorrect because the glucose value is not irrelevant in the sense implied; rather, a normal value must not be used to exclude the diagnosis, and these agents can indeed cause perioperative ketoacidosis.
Option D: Option D is incorrect because increasing the dose during fasting raises, not lowers, the risk of euglycemic ketoacidosis.
Option E: Option E is incorrect because euglycemic ketoacidosis specifically occurs without markedly elevated glucose, so a normal glucose cannot exclude it.
11. A patient with peripheral arterial disease and a prior toe amputation needs an SGLT-2 inhibitor for heart failure. Integrating what is known about agent-specific safety signals with the goal of an outcome-proven choice, which decision is best supported?
A) Select dapagliflozin or empagliflozin rather than canagliflozin: the increased lower-extremity amputation signal is considered largely canagliflozin-specific and not consistently replicated across the class, and dapagliflozin and empagliflozin carry proven heart failure benefit, making them the better-justified choice in a patient with prior amputation
B) Select canagliflozin preferentially, because its amputation signal indicates it improves limb perfusion in patients with peripheral arterial disease
C) Avoid all SGLT-2 inhibitors entirely, because the amputation signal is a uniform class effect that applies equally to every agent
D) Select ertugliflozin, because it is the agent with proven heart failure outcome benefit and the lowest amputation risk
E) The choice of agent is irrelevant to amputation risk, so select whichever agent is cheapest without regard to the prior amputation
ANSWER: A
Rationale:
This integrates agent-specific safety with the need for an outcome-proven agent. The increased lower-extremity amputation signal was identified with canagliflozin (in the CANVAS program) and is considered largely canagliflozin-specific, not a consistent class effect. Dapagliflozin and empagliflozin carry proven heart failure benefit and are not implicated in the amputation signal, so they are the better-justified choice in a patient with peripheral arterial disease and prior amputation.
Option B: Option B is incorrect because the amputation signal indicates increased risk with canagliflozin, not improved limb perfusion.
Option C: Option C is incorrect because the signal is not a uniform class effect, so avoiding all SGLT-2 inhibitors is unwarranted and would forgo heart failure benefit.
Option D: Option D is incorrect because ertugliflozin lacks a proven heart failure outcome indication, so it is not the appropriate outcome-driven choice.
Option E: Option E is incorrect because agent choice is relevant to amputation risk given the canagliflozin-specific signal, so selecting purely on cost ignores a material safety consideration.
12. Heart failure with preserved ejection fraction had long resisted therapies showing outcome benefit until an SGLT-2 inhibitor demonstrated benefit. Integrating the proposed mechanisms of this class, which synthesis best explains how benefit can occur even when ejection fraction is preserved?
A) Benefit in preserved ejection fraction is explained solely by positive inotropy that raises ejection fraction into the normal range
B) Benefit is explained entirely by low-density lipoprotein lowering and plaque regression, which reverse diastolic dysfunction within weeks
C) Benefit is explained by potent direct coronary vasodilation that increases myocardial oxygen supply independent of loading conditions
D) Benefit is explained by strong renin-angiotensin and sympathetic activation that augments contractility during diuresis
E) Benefit reflects mechanisms largely independent of ejection fraction: preload reduction through osmotic diuresis and natriuresis (without the neurohormonal activation of aggressive diuresis), reduced epicardial fat and pericardial constraint, anti-fibrotic effects, and a metabolic shift toward more oxygen-efficient ketone (beta-hydroxybutyrate) oxidation in the failing heart
ANSWER: E
Rationale:
This synthesizes the proposed mechanisms to explain a preserved-ejection-fraction benefit. The class acts largely independent of ejection fraction: preload reduction through osmotic diuresis and natriuresis (achieved without the neurohormonal activation typical of aggressive diuresis), reduced epicardial fat with less pericardial constraint, anti-fibrotic effects, and a metabolic shift toward more oxygen-efficient ketone (beta-hydroxybutyrate) oxidation in the energy-depleted myocardium. These mechanisms improve outcomes whether or not ejection fraction is reduced.
Option A: Option A is incorrect because the benefit is not explained by positive inotropy raising ejection fraction; the class does not act as a direct inotrope.
Option B: Option B is incorrect because SGLT-2 inhibitors do not act by lowering low-density lipoprotein or regressing plaque, and that would not reverse diastolic dysfunction in weeks.
Option C: Option C is incorrect because potent direct coronary vasodilation independent of loading is not the proposed mechanism.
Option D: Option D is incorrect because the class produces volume effects without strong neurohormonal activation, and it does not work by augmenting contractility through renin-angiotensin and sympathetic activation.
13. A patient on basal insulin and a sulfonylurea is starting an SGLT-2 inhibitor, and the team is also weighing whether to add a second SGLT-2 inhibitor for additive glycosuria. Integrating combination principles and hypoglycemia risk, which plan is correct?
A) Add a second SGLT-2 inhibitor for additive glycosuria and increase the basal insulin at the same time to prevent loss of control
B) Stop the basal insulin entirely the day the SGLT-2 inhibitor is started, and continue the sulfonylurea unchanged
C) Do not combine two SGLT-2 inhibitors; when adding the SGLT-2 inhibitor to insulin, reduce the basal insulin by roughly 20% at initiation to limit hypoglycemia, and be aware that the sulfonylurea independently adds hypoglycemia risk that should be monitored
D) Combine two SGLT-2 inhibitors but leave both the insulin and sulfonylurea doses unchanged, since SGLT-2 inhibitors carry no hypoglycemia risk in any combination
E) Triple the SGLT-2 inhibitor dose to compensate for the insulin and sulfonylurea, then discontinue both other agents
ANSWER: C
Rationale:
This integrates the combination rules with hypoglycemia management. Two SGLT-2 inhibitors should never be combined. When an SGLT-2 inhibitor is added to insulin, the insulin dose is typically reduced by about 20% at initiation to limit hypoglycemia from the added glucose-lowering effect. The sulfonylurea, which acts by driving insulin secretion, independently contributes hypoglycemia risk that should be monitored.
Option A: Option A is incorrect because two SGLT-2 inhibitors should not be combined and the insulin should be reduced, not increased.
Option B: Option B is incorrect because insulin is dose-reduced (about 20%), not stopped entirely, and the sulfonylurea's hypoglycemia contribution should not be ignored.
Option D: Option D is incorrect because two SGLT-2 inhibitors should not be combined, and the statement that there is no hypoglycemia risk in any combination is wrong given concurrent insulin and a sulfonylurea.
Option E: Option E is incorrect because tripling the SGLT-2 inhibitor dose is not an appropriate strategy and abruptly discontinuing insulin could destabilize control.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.